Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer
Carissa E Chu,Mohammed Alshalalfa,Martin Sjöström,Shuang G Zhao,Yang Liu,Jonathan Chou,Annika Herlemann,Brandon Mahal,Amar U Kishan,Daniel E Spratt,Matthew Cooperberg,Eric Small,Anthony Wong,Sima Porten,Thomas A Hope,Ashley E Ross,Elai Davicioni,Paul Nguyen,R Jeffrey Karnes,Peter R Carroll,Edward Schaeffer,Felix Y Feng,Carissa E. Chu,Shuang G. Zhao,Amar U. Kishan,Daniel E. Spratt,Thomas A. Hope,Ashley E. Ross,R. Jeffrey Karnes,Peter R. Carroll,Felix Y. Feng
DOI: https://doi.org/10.1016/j.eururo.2021.03.017
IF: 24.267
2021-06-01
European Urology
Abstract:<p><sup>18</sup>F-Fluciclovine-based positron emission tomography (PET) imaging is recommended in the USA for biochemical recurrence (BCR) after prostate cancer treatment. However, prostate-specific membrane antigen (PSMA)-based PET imaging is more common worldwide, supported by international guidelines, and is now approved by the Food and Drug Administration in the USA for initial staging of primary prostate cancer. Little is known about the molecular profiles of lesions detected by PSMA-targeted PET/computed tomography (CT) versus <sup>18</sup>F-fluciclovine PET/CT. We examined the expression of <em>PSMA</em> (<em>FOLH1</em>) and the fluciclovine transporter genes <em>LAT1–4</em> and <em>ASCT1/2</em> in a combined cohort of more than 18 000 radical prostatectomy specimens and their associations with clinical outcomes. Expression of <em>PSMA</em> and all but one fluciclovine transporter gene was higher in prostate cancer than in benign tissue. <em>PSMA</em> expression was associated with Gleason score (GS) ≥8 and lymph node involvement (LNI), and had a positive linear correlation with Decipher risk score. By contrast, expression of the fluciclovine transporters <em>LAT2</em>, <em>LAT3</em>, and <em>ASCT2</em> was negatively associated with GS ≥ 8, LNI, and high Decipher score. The top decile of <em>PSMA</em> expression was associated with poorest metastasis-free survival (MFS), while the bottom deciles of <em>LAT3</em> and <em>ASCT2</em> expression were associated with poorest MFS.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Patient summary</h3><p>We measured the expression of genes that encode the targets for two different radiotracers in PET (positron emission tomography) scans of the prostate. We found that <em>PSMA</em> gene expression (PSMA-based tracer) is associated with worse clinical outcomes, while expression of <em>ASCT2</em>, <em>LAT2</em>, and <em>LAT3</em> genes (fluciclovine tracer) is associated with better outcomes.</p>
urology & nephrology